U.S. markets open in 1 hour 2 minutes

The Independent Director of Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Jeffrey George, Just Bought A Few More Shares

Simply Wall St

Even if it's not a huge purchase, we think it was good to see that Jeffrey George, the Independent Director of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) recently shelled out US$99k to buy stock, at US$4.16 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.

View our latest analysis for Amneal Pharmaceuticals

The Last 12 Months Of Insider Transactions At Amneal Pharmaceuticals

In the last twelve months, the biggest single purchase by an insider was when Co-Founder Chirag Patel bought US$975k worth of shares at a price of US$3.97 per share. That means that an insider was happy to buy shares at around the current price of US$4.12. Of course they may have changed their mind. But this suggests they are optimistic. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider purchases were made at close to current prices.

While Amneal Pharmaceuticals insiders bought shares during the last year, they didn't sell. They paid about US$3.36 on average. Although they bought at below the recent share price, it is good to see that insiders are willing to invest in the company. You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NYSE:AMRX Recent Insider Trading May 17th 2020

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Does Amneal Pharmaceuticals Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Amneal Pharmaceuticals insiders own about US$64m worth of shares. That equates to 5.2% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The Amneal Pharmaceuticals Insider Transactions Indicate?

It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest Amneal Pharmaceuticals insiders are well aligned, and that they may think the share price is too low. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To that end, you should learn about the 2 warning signs we've spotted with Amneal Pharmaceuticals (including 1 which is potentially serious).

Of course Amneal Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.